Acarbose
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Acarbose: alpha-glucosidase inhibitor → focal stiff limb syndrome
One-Sentence Summary
Acarbose is an oral alpha-glucosidase inhibitor that acts locally in the gut to delay carbohydrate absorption. The TxGNN model predicts it may be relevant to focal stiff limb syndrome, with a score of 0.9965. There are no clinical trials and no publications that study this disease, so the prediction rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | focal stiff limb syndrome |
| TxGNN Prediction Score | 0.9965 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available in the data compiled for this report. Acarbose is known as an alpha-glucosidase inhibitor that acts locally in the gut to delay carbohydrate absorption and blunt postprandial glucose rises.
Focal stiff limb syndrome is a neurological disorder within the stiff-person spectrum, linked to impaired GABAergic inhibition or autoimmune mechanisms. No mechanistic link to alpha-glucosidase inhibition has been identified. The only loose connection is that autoimmune conditions related to this spectrum can co-occur with diabetes, which does not support acarbose as a treatment.
The score is a model output only. It is not a clinical finding and should not be read as evidence of efficacy.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 13869Y | GLYBOSAY | Tablet 100 mg | Not recorded in the local data |
Safety Considerations
Detailed label warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for full safety information.
- Drug Interactions: The interaction query returned 100 entries. Examples at moderate level include acetazolamide, salbutamol, aloe vera leaf, alpelisib, amprenavir, aripiprazole, asenapine, atazanavir, bedaquiline, bendroflumethiazide, benzphetamine, benzthiazide and betamethasone. Minor-level examples include albiglutide, alclometasone (topical), lipoic acid, amcinonide and anisindione.
Conclusion and Next Steps
Decision: Hold
Rationale: The evidence level is L5. No trials or publications study focal stiff limb syndrome, and no plausible mechanistic link to acarbose has been identified.
To proceed, the following is needed:
- Any clinical or preclinical study directly addressing focal stiff limb syndrome
- A plausible, documented mechanism linking alpha-glucosidase inhibition to the disease
- Mechanism of action data and TGA Product Information warnings and contraindications for review
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.